JP2015531776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531776A5 JP2015531776A5 JP2015530131A JP2015530131A JP2015531776A5 JP 2015531776 A5 JP2015531776 A5 JP 2015531776A5 JP 2015530131 A JP2015530131 A JP 2015530131A JP 2015530131 A JP2015530131 A JP 2015530131A JP 2015531776 A5 JP2015531776 A5 JP 2015531776A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- compound
- methyl
- formula
- deuterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261696727P | 2012-09-04 | 2012-09-04 | |
| US61/696,727 | 2012-09-04 | ||
| PCT/US2013/057786 WO2014039421A1 (en) | 2012-09-04 | 2013-09-03 | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018061024A Division JP2018123142A (ja) | 2012-09-04 | 2018-03-28 | ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015531776A JP2015531776A (ja) | 2015-11-05 |
| JP2015531776A5 true JP2015531776A5 (https=) | 2016-10-27 |
Family
ID=49226507
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530131A Pending JP2015531776A (ja) | 2012-09-04 | 2013-09-03 | ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法 |
| JP2018061024A Withdrawn JP2018123142A (ja) | 2012-09-04 | 2018-03-28 | ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018061024A Withdrawn JP2018123142A (ja) | 2012-09-04 | 2018-03-28 | ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9682952B2 (https=) |
| EP (1) | EP2892887B1 (https=) |
| JP (2) | JP2015531776A (https=) |
| CN (1) | CN104755472A (https=) |
| ES (1) | ES2814952T3 (https=) |
| WO (1) | WO2014039421A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2428513T3 (en) | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
| JP5959543B2 (ja) | 2011-03-11 | 2016-08-02 | セルジーン コーポレイション | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンの固体形態、並びにそれらの医薬組成物及び使用 |
| AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| ES2814952T3 (es) | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
| CA2935495C (en) * | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| EP2968334A4 (en) * | 2013-03-14 | 2016-08-03 | Deuterx Llc | 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES |
| SMT201700513T1 (it) | 2013-05-01 | 2018-01-11 | Celgene Corp | Sintesi di 3-(5-ammino-2-metil-4-ossochinazolin-3(4h)-il) piperidin-2,6-dione |
| WO2016109360A1 (en) * | 2014-12-29 | 2016-07-07 | Auspex Pharmaceuticals, Inc. | Dihydroquinazoline inhibitors of viral terminase |
| EP3316888A1 (en) | 2015-07-02 | 2018-05-09 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| EP3404024B1 (en) * | 2016-01-14 | 2020-11-18 | Kangpu Biopharmaceuticals, Ltd. | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications |
| WO2018045294A1 (en) * | 2016-09-02 | 2018-03-08 | Cempra Pharmaceuticals, Inc. | Processes for preparing fluoroketolides |
| CN106518754B (zh) * | 2016-09-28 | 2019-05-31 | 重庆中邦科技有限公司 | 一种制备2,3-二氯吡啶的方法 |
| US10933059B2 (en) | 2016-12-16 | 2021-03-02 | Kangpu Biopharmaceuticals. Ltd. | Combination, application thereof and treatment method |
| TWI791552B (zh) | 2017-07-10 | 2023-02-11 | 美商西建公司 | 抗增生化合物及其使用方法 |
| WO2022002022A1 (zh) * | 2020-06-29 | 2022-01-06 | 北京拓界生物医药科技有限公司 | 一种放射性核素标记物及其应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| WO2005049613A1 (en) | 2003-11-14 | 2005-06-02 | Merck Sharp & Dohme Limited | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| GB0327323D0 (en) * | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
| GB0506147D0 (en) | 2005-03-24 | 2005-05-04 | Merck Sharp & Dohme | Therapeutic agents |
| US20090298856A1 (en) | 2005-05-11 | 2009-12-03 | Rebecca Elizabeth Brown | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) |
| GB0509573D0 (en) | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| EP1957439A2 (en) * | 2005-11-15 | 2008-08-20 | Syngeta Participations AG | Process for the production of biphenyls |
| CN101415688A (zh) | 2006-04-05 | 2009-04-22 | 阿斯利康(瑞典)有限公司 | 具有b-raf抑制活性的喹唑啉酮衍生物 |
| WO2007113557A1 (en) | 2006-04-05 | 2007-10-11 | Astrazeneca Ab | Substituted quinazolines with anti-cancer activity |
| CN101421253A (zh) | 2006-04-18 | 2009-04-29 | 阿斯利康(瑞典)有限公司 | 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物 |
| US20090227579A1 (en) * | 2006-06-23 | 2009-09-10 | Astrazeneca Ab | Pteridine Derivatives and their Use as Cathespin Inhibitors |
| DK2428513T3 (en) * | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
| WO2011047129A1 (en) | 2009-10-15 | 2011-04-21 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| US20120302605A1 (en) | 2010-11-18 | 2012-11-29 | Deuteria Pharmaceuticals, Llc | 3-deutero-pomalidomide |
| JP5959543B2 (ja) | 2011-03-11 | 2016-08-02 | セルジーン コーポレイション | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンの固体形態、並びにそれらの医薬組成物及び使用 |
| AU2012229300B2 (en) | 2011-03-11 | 2017-04-20 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione |
| AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| CA2834535A1 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| EP2802877A1 (en) | 2012-01-13 | 2014-11-19 | Celgene Corporation | Biomarkers for the treatment of hepatocellular carcinoma |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| ES2814952T3 (es) | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
| MX2015003114A (es) | 2012-09-10 | 2015-07-06 | Celgene Corp | Metodos para el tratamiento de cancer de mama localmente avanzado. |
| CA2935495C (en) * | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| CN105050624A (zh) | 2013-03-14 | 2015-11-11 | 细胞基因公司 | 利用阿普斯特来治疗银屑病关节炎的方法 |
| EP2968334A4 (en) | 2013-03-14 | 2016-08-03 | Deuterx Llc | 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES |
| CN105358177B (zh) | 2013-04-17 | 2018-11-23 | 西格诺药品有限公司 | 包含tor激酶抑制剂和imid化合物的联合疗法用于治疗癌症 |
| TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| BR112015026297B1 (pt) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit |
| SMT201700513T1 (it) | 2013-05-01 | 2018-01-11 | Celgene Corp | Sintesi di 3-(5-ammino-2-metil-4-ossochinazolin-3(4h)-il) piperidin-2,6-dione |
| TW201534305A (zh) | 2013-05-03 | 2015-09-16 | Celgene Corp | 使用組合療法治療癌症之方法 |
| IL278381B2 (en) | 2013-12-06 | 2024-08-01 | Celgene Corp | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| TW201540323A (zh) | 2014-01-15 | 2015-11-01 | Celgene Corp | ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物 |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| EP3116872A4 (en) | 2014-03-14 | 2017-08-30 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2015200795A1 (en) | 2014-06-27 | 2015-12-30 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
| WO2016007854A1 (en) | 2014-07-11 | 2016-01-14 | Celgene Corporation | Combination therapy for cancer |
| WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
| CA2957225A1 (en) | 2014-08-07 | 2016-02-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| US10092541B2 (en) | 2014-08-15 | 2018-10-09 | Celgene Corporation | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
| WO2016060702A1 (en) | 2014-10-13 | 2016-04-21 | Celgene Corporaton | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| WO2016153948A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders |
| US10450299B2 (en) | 2015-03-25 | 2019-10-22 | Centre National De La Recherche Scientifique (Cnrs) | Substituted quinazoline derivatives as DNA methyltransferase inhibitors |
| TW201642857A (zh) | 2015-04-06 | 2016-12-16 | 西建公司 | 以組合療法治療肝細胞癌 |
-
2013
- 2013-09-03 ES ES13765835T patent/ES2814952T3/es active Active
- 2013-09-03 JP JP2015530131A patent/JP2015531776A/ja active Pending
- 2013-09-03 US US14/425,479 patent/US9682952B2/en not_active Expired - Fee Related
- 2013-09-03 CN CN201380056088.2A patent/CN104755472A/zh active Pending
- 2013-09-03 WO PCT/US2013/057786 patent/WO2014039421A1/en not_active Ceased
- 2013-09-03 EP EP13765835.7A patent/EP2892887B1/en active Active
-
2017
- 2017-05-12 US US15/594,273 patent/US20180093965A1/en not_active Abandoned
-
2018
- 2018-03-28 JP JP2018061024A patent/JP2018123142A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015531776A5 (https=) | ||
| Wang et al. | Recent advances in nucleophile-triggered CO 2-incorporated cyclization leading to heterocycles | |
| ES2693320T3 (es) | Método para la producción compuestos heterocíclicos condensados | |
| JP6147279B2 (ja) | オレキシン−２受容体アンタゴニストの合成において有用な方法および化合物 | |
| CN104918944B (zh) | 螺环异噁唑啉衍生物的合成 | |
| JPWO2016152886A1 (ja) | ピラゾール誘導体の製造方法 | |
| ES3035360T3 (en) | Process for preparing a cot inhibitor compound | |
| TWI543964B (zh) | 經克來森重排反應之雙環化合物之製造方法 | |
| CN114031572B (zh) | 用于制备取代的环丝氨酸的方法 | |
| TWI666211B (zh) | 一種曲貝替定的製備方法及其中間體 | |
| ES2629313T3 (es) | Procedimiento de preparación de 1-([1,3]dioxolan-4-ilmetil)-1H-pirazol-3-ilamina | |
| WO2011161612A1 (en) | Process for preparing 4-hydroxypyridines | |
| Raskil’dina et al. | Selective functionalization of the primary hydroxy group in triols | |
| ES2774775T3 (es) | Berbinas sustituidas y su síntesis | |
| JP6001168B2 (ja) | フェニルアルキルスルファメート化合物及びこれを含む筋弛緩剤組成物 | |
| Lago-Santome et al. | A convergent approach to the dioxaadamantane core of (±)-tetrodotoxin | |
| CN110272414B (zh) | 一种唑吡坦的制备方法 | |
| US8901302B2 (en) | Pyrazino[2,3-D]isoxazole derivative which is useful as a production intermediate of pyrazine carboxamide derivative | |
| JP6289177B2 (ja) | 含窒素複素環化合物の製造方法 | |
| JP2012509267A5 (ja) | （Ｒ）−３−（２，３−ジヒドロキシプロピル）−６−フルオロ−５−（２−フルオロ−４−ヨードフェニルアミノ）−８−メチルピリド［２，３−ｄ］ピリミジン−４，７（３Ｈ，８Ｈ）−ジオンを製造するためのプロセス及びその中間体 | |
| AU2012253188A1 (en) | Process for the preparation of morphine analogs via metal catalyzed N-demethylation/functionalization and intramolecular group transfer | |
| CA2762022A1 (en) | Redox drug derivatives | |
| US9181237B2 (en) | Substituted berbines and their synthesis | |
| JP5309680B2 (ja) | フッ素化エステル化合物の製造方法及びその中間体 | |
| Wappes | Radical sp3 CH Functionalization of Amines and Alcohols |